Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...
Dan Veru, CIO at Palisade Capital, says tariffs are negotiation tools, with companies adapting, though lower-margin ...
Veru Inc (VERU) advances its biopharmaceutical pipeline with promising clinical results while navigating financial hurdles ...
Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...
Discover Veru Inc.'s latest Q1 2025 updates on enobosarm & sabizabulin trials, financials, & strategic pivots in cardiometabolic and inflammation treatment.
Gladstone Institutional Advisory LLC lifted its position in Veru Inc. (NASDAQ:VERU – Free Report) by 52.7% in the 4th quarter, according to the company in its most recent filing with the Securities ...
Veru Inc. (NASDAQ:VERU – Get Free Report) was the recipient of a large increase in short interest in the month of January.As of January 31st, there was short interest totalling 14,620,000 shares ...
Veru (NASDAQ:VERU) Inc. reported its Q1 FY2025 earnings, revealing a net loss per share of $0.06, which was better than the projected loss of $0.08. The company's revenue reached $3.2 million ...
Cash, cash equivalents, and restricted cash were $26.6M as of December 31, 2024 versus $24.9M as of September 30, 2024. “We are very excited ...
Novel enobosarm modified release oral formulation Veru is currently developing a novel, patentable, modified release formulation for enobosarm. We anticipate the actual formulation ...